




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 207/12, A61K 31/40</b>		A1	(11) International Publication Number: <b>WO 98/40353</b> (43) International Publication Date: 17 September 1998 (17.09.98)
(21) International Application Number:	PCT/DK98/00084	(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	6 March 1998 (06.03.98)	(30) Priority Data:	0248/97 7 March 1997 (07.03.97) DK
(71) Applicant (for all designated States except US):	NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).	(72) Inventors; and	
(75) Inventors/Applicants (for US only):	KRISTIANSEN, Marit [DK/DK]; Gustav Esmanns Allé 2, DK-2860 Søborg (DK). JAKOBSEN, Palle [DK/DK]; Langkær Vænge 14, DK-3500 Værløse (DK). LUNDBECK, Jane, Marie [DK/DK]; Evas Allé 19, DK-2600 Glostrup (DK).	(74) Common Representative:	NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).

## (54) Title: NOVEL HETEROCYCLIC COMPOUNDS

## (57) Abstract

The present invention relates to novel pyrrolidine compounds having general formula (I) and pharmaceutically acceptable acid addition salts or hydrates or prodrugs hereof, wherein R<sup>1</sup> is straight or branched C<sub>1-14</sub>-alkyl optionally substituted with C<sub>3-7</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, phenoxy, perhalomethyl, halogen, optionally substituted phenyl; R<sup>2</sup> is optionally C=R<sup>2</sup> or C-R<sup>2</sup>, R<sup>2</sup> is oxygen, hydroxy, halogen, amino or mercapto, R<sup>3</sup> and R<sup>4</sup> independently are hydroxy, halogen, amino or mercapto, the use of these compounds as medicament, the use of these medicaments in the treatment of diabetes, pharmaceutical compositions containing these compounds and methods of preparing the compounds.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NOVEL HETEROCYCLIC COMPOUNDS

The present invention relates to novel compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or type 2 diabetes) including overnight or meal treatment and treatment or prevention of long-term complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or myocardial ischemia; pharmaceutical compositions containing these compounds, and methods of preparing the compounds.

Diabetes is characterized by an impaired glucose metabolism manifesting itself among other things by an elevated blood glucose level in the diabetic patients. Underlying defects lead to a classification of diabetes into two major groups: type 1 diabetes, or insulin demanding diabetes mellitus (IDDM), which arises when patients lack  $\beta$ -cells producing insulin in their pancreatic glands, and type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM), which occurs in patients with an impaired  $\beta$ -cell function besides a range of other abnormalities.

Type 1 diabetic patients are currently treated with insulin, while the majority of type 2 diabetic patients are treated either with sulfonylureas that stimulate  $\beta$ -cell function or with agents that enhance the tissue sensitivity of the patients towards insulin or with insulin. Among the agents applied to enhance tissue sensitivity towards insulin metformin is a representative example. Even though sulfonylureas are widely used in the treatment of NIDDM this therapy is, in most instances, not satisfactory: In a large number of NIDDM patients sulfonylureas do not suffice to normalize blood sugar levels and the patients are, therefore, at high risk for acquiring diabetic complications. Also, many patients gradually lose the ability to respond to treatment with sulfonylureas and are thus gradually forced into insulin treatment. This shift of patients from oral hypoglycaemic agents to insulin therapy is usually ascribed to exhaustion of the  $\beta$ -cells in NIDDM patients.

In normals as well as in diabetics, the liver produces glucose in order to avoid hypoglycaemia. This glucose production is derived either from the release of glucose from glycogen stores or from gluconeogenesis, which is a de novo intracellular synthesis of glucose. In type

2 diabetes, however, the regulation of hepatic glucose output is poorly controlled and is increased, and may be doubled after an overnight fast. Moreover, in these patients there exists a strong correlation between the increased fasting plasma glucose levels and the rate of hepatic glucose production (reviewed in R.A. De Fronzo: Diabetes **37** (1988), 667 - 687; A. 5 Consoli: Diabetes Care **15** (1992), 430 - 441; and J.E. Gerich: Horm.Metab.Res. **26** (1992), 18 - 21). Similarly, hepatic glucose production will be increased in type 1 diabetes, if the disease is not properly controlled by insulin treatment. Since existing forms of therapy of diabetes does not lead to sufficient glycaemic control and therefore are unsatisfactory, there is a great demand for novel therapeutic approaches. Since the liver in diabetes is known to 10 have an increased glucose production, compounds inhibiting this activity are highly desirable. Recently, patent applications on inhibitors of the liver specific enzyme, glucose-6-phosphatase, which is necessary for the release of glucose from the liver, have been filed, for example German Offenlegungsschrift Nos. 4,202,183 and 4,202,184 and Japanese patent application No. 4-58565. All these known compounds are benzene derivatives. Substituted N- 15 (indole-2-carbonyl)-glycinamides acting as glycogen phosphorylase inhibitors are disclosed in PCT-publications No. WO96/39384 and WO96/39385.

Atherosclerosis, a disease of the arteries, is recognized to be the leading cause of death in the United States and Western Europe. The pathological sequence leading to atherosclerosis and occlusive heart disease is well known. The earliest stage in this sequence is the formation of "fatty streaks" in the carotid, coronary and cerebral arteries and in the aorta. These 20 lesions are yellow in color due to the presence of lipid deposits found principally within smooth-muscle cells and in macrophages of the intima layer of the arteries and aorta. Further, it is postulated that most of the cholesterol found within the fatty streaks, in turn, give 25 rise to development of the "fibrous plaque", which consists of accumulated intimal smooth muscle cells laden with lipid and surrounded by extracellular lipid, collagen, elastin and proteoglycans. The cells plus matrix form a fibrous cap that covers a deeper deposit of cell debris and more extra cellular lipid. The lipid is primarily free and esterified cholesterol. The fibrous plaque forms slowly, and is likely in time to become calcified and necrotic, advancing 30 to the "complicated lesion" which accounts for the arterial occlusion and tendency toward mural thrombosis and arterial muscle spasm that characterize advanced atherosclerosis.

Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor in causing cardiovascular disease (CVD) due to atherosclerosis. In recent years, leaders of the

medical profession have placed renewed emphasis on lowering plasma cholesterol levels, and low density lipoprotein cholesterol in particular, as an essential step in prevention of CVD. The upper limits of "normal" are now known to be significantly lower than heretofore appreciated. As a result, large segments of Western populations are now realized to be at 5 particular high risk. Such independent risk factors include glucose intolerance, left ventricular hypertrophy, hypertension, and being of the male sex. Cardiovascular disease is especially prevalent among diabetic subjects, at least in part because of the existence of multiple independent risk factors in this population. Successful treatment of hyperlipidemia in the general population, and in diabetic subjects in particular, is therefore of exceptional medical importance. 10

Hypertension (or high blood pressure) is a condition which occurs in the human population as a secondary symptom to various other disorders such as renal artery stenosis, pheochromocytoma or endocrine disorders. However, hypertension is also evidenced in many 15 patients in whom the causative agent or disorder is unknown. While such "essential" hypertension is often associated with disorders such as obesity, diabetes and hypertriglyceridemia, the relationship between these disorders has not been elucidated. Additionally, many patients display the symptoms of high blood pressure in the complete absence of any other signs of disease or disorder.

20 It is known that hypertension can directly lead to heart failure, renal failure and stroke (brain hemorrhaging). These conditions are capable of causing short-term death in a patient. Hypertension can also contribute to the development of atherosclerosis and coronary disease. These conditions gradually weaken a patient and can lead to long-term death.

25 The exact cause of essential hypertension is unknown, though a number of factors are believed to contribute to the onset of the disease. Among such factors are stress, uncontrolled emotions, unregulated hormone release (the renin, angiotensin, aldosterone system), excessive salt and water due to kidney malfunction, wall thickening and hypertrophy of the 30 vasculature resulting in constricted blood vessels and genetic factors.

The treatment of essential hypertension has been undertaken bearing the foregoing factors in mind. Thus, a broad range of beta-blockers, vasoconstrictors, angiotensin converting enzyme inhibitors and the like have been developed and marketed as antihypertensives. The

treatment of hypertension utilizing these compounds have proven beneficial in the prevention of short-interval deaths such as heart failure, renal failure and brain hemorrhaging. However, the development of atherosclerosis or heart disease due to hypertension over a long period of time remains a problem. This implies that although high blood pressure is being reduced, 5 the underlying cause of essential hypertension is not responding to this treatment.

Hypertension has been associated with elevated blood insulin levels, a condition known as hyperinsulinemia. Insulin, a peptide hormone whose primary actions are to promote glucose utilization, protein synthesis and the formation and storage of neutral lipids, also acts to promote 10 vascular cell growth and increase renal sodium retention among other things. These latter functions can be accomplished without affecting glucose levels and are known causes of hypertension. Peripheral vasculature growth, for example, can cause constriction of peripheral capillaries; while sodium retention increases blood volume. Thus, the lowering of insulin levels in hyperinsulinemics can prevent abnormal vascular growth and renal sodium 15 retention caused by high insulin levels and thereby alleviate hypertension.

Cardiac hypertrophy is a significant risk factor in the development of sudden death, myocardial infarction, and congestive heart failure. These cardiac events are due, at least in part, to increased susceptibility to myocardial injury after ischemia and reperfusion which can occur 20 in out-patient as well as perioperative settings. There is an unmet medical need to prevent or minimize adverse myocardial perioperative outcomes, particularly perioperative myocardial infarction. Both non-cardiac and cardiac surgery are associated with substantial risks for myocardial infarction or death. Some 7 million patients undergoing non-cardiac surgery are considered to be at risk, with incidences of perioperative death and serious cardiac complications 25 as high as 20-25% in some series. In addition, of the 400,000 patients undergoing coronary by-pass surgery annually, perioperative myocardial infarction is estimated to occur in 5% and death in 1-2%. There is currently no drug therapy in this area which reduces damage to cardiac tissue from perioperative myocardial ischemia or enhances cardiac resistance to ischemic episodes. Such a therapy is anticipated to be life-saving and reduce 30 hospitalizations, enhance quality of life and reduce overall health care costs of high risk patients.

One object of the present invention is to provide compounds which can be used as medications for treating one or more of the above-mentioned diseases and disorders.

A further object of this invention is to provide compounds which can effectively be used in the treatment of diabetes, preferably type II diabetes, including overnight or meal treatment, and preferably for the treatment of increased plasma glucose levels.

5 Besides, it is an object of the invention to provide compounds having a reduced risk of side effects, and which can effectively be used as medicaments for long-term treatment.

10 A still further object of this invention is to provide compounds which can effectively be used as inhibitors of glucose production from the liver.


15 A still further object of this invention is to provide further compounds which can be effectively used as phosphorylase inhibitors, preferably as glycogen phosphorylase inhibitors.

20 It has now been found that members of a novel group of pyrrolidine compounds have interesting pharmacological properties. For example, the compounds of this invention can be used in the treatment of diabetes. Especially, the compounds of this invention are active as inhibitors of glucose production from the liver. Consequently, the compounds of this invention can be used for the treatment of the increased plasma glucose levels in diabetics.

25 Accordingly, it is an object of the invention to provide such novel pyrrolidine compounds.

#### DETAILED DESCRIPTION OF THE INVENTION

25 The compounds of the invention are compounds of the general formula I



and pharmaceutically acceptable acid addition salts or hydrates or prodrugs hereof, wherein R<sup>1</sup> is straight or branched C<sub>1-14</sub>-alkyl optionally substituted with C<sub>3-7</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, phenoxy, perhalomethyl, halogen, optionally substituted phenyl;

5      C---R<sup>2</sup> is optionally    C= R<sup>2</sup>    or    C—R<sup>2</sup>

R<sup>2</sup> is oxygen, hydroxy, halogen, amino or mercapto,

R<sup>3</sup> and R<sup>4</sup> independently are hydroxy, halogen, amino or mercapto.

10

The compounds of formula I may be presented as a mixture of enantiomers which, if desired, may be resolved into the individual pure enantiomers. This resolution may conveniently be performed by fractional crystallization from various solvents, of the salts of compounds of the formula I with optical active acids or by other methods known *per se*, for example, chiral column chromatography. This invention includes all isomers, whether resolved or mixtures thereof.

Examples of pharmaceutically acceptable salts are acid addition salts with non-toxic acids, either inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic and ethanesulfonic acid, malonic acid, oxalic acid, maleic acid, pyruvic acid, tartaric acid, fumaric acid, mandelic acid, cinnamic acid, picric acid and the like acids, and include the pharmaceutically acceptable salts listed in *Journal of Pharmaceutical Science*, 66, 2 (1977) and incorporated herein by reference; pharmaceutically acceptable metal salts, such as lithium, sodium, potassium, or magnesium salts and the like. Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form. The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.

In the above structural formula and throughout the present specification, the following terms have the indicated meaning:

5 The term "C<sub>1-6</sub>-alkoxy" as used herein, alone or in combination, is intended to include those C<sub>1-6</sub> alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy. Examples of branched alkoxy groups are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, and 10 isohexoxy. Examples of cyclic alkoxy groups are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy.

15 The term "C<sub>3-7</sub>-cycloalkyl" as used herein refers to a radical of a saturated cyclic hydrocarbon with the indicated number of carbons such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

The term "halogen" means fluorine, chlorine, bromine or iodine.

20 The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or triiodomethyl.

25 The term "C<sub>1-14</sub>-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms. Typical C<sub>1-14</sub> alkyl groups include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl, tridecyl and the like. The term "C<sub>1-14</sub>-alkyl" as used herein also includes secondary C<sub>3-6</sub>-alkyl and tertiary C<sub>4-6</sub>-alkyl.

30 The term "prodrug" as used herein refers to e.g. to compounds of formula I in which an ester group has been introduced.

Certain of the above defined terms may occur more than once in the above formula I, and upon such occurrence each term shall be defined independently of the other.

The compounds of the invention may have one or more asymmetric centres and it is intended that stereoisomers (optical isomers), as separated, pure, or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the invention.

In a preferred embodiment  $C\dash R^2$  is C-R2 wherein R2 has the meaning defined above, and preferably is hydroxy.

10

In another preferred embodiment R3 and R4 are both hydroxy.

Preferred compounds of the invention are:

- 15 (3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,
- (3R,4R)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,
- (3R,4R)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,
- (3R,4R)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,
- (3R,4R)-2-(1-hydroxyphenylbutyl)-3,4-pyrrolidinediol, and
- 20 (3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol.

or pharmaceutically acceptable salts or hydrates thereof as defined herein, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

25 The present invention also relates to an optical isomer or mixture of optical isomers, including a racemic mixture of compounds of formula I selected from the group consisting of:

- (2R,3R,4R)-2-acetyl-3,4-pyrrolidinediol,
- (2R,3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,
- 30 (2R,3R,4R)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,
- (2R,3R,4R)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,
- (2R,3R,4R)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,
- (2S,3S,4S)-2-acetyl-3,4-pyrrolidinediol,

(2S,3S,4S)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,  
5 (2R,3R,4R)-2-((1R)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-(1R)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1R)-1-hydroxypentyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1R)-1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
10 (2S,3S,4S)-2-((1R)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxypentyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1S)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
15 (2R,3R,4R)-2-((1S)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1S)-1-hydroxypentyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1S)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1S)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
20 (2S,3S,4S)-2-((1S)-1-hydroxypentyl)-3,4-pyrrolidinediol, and  
or a pharmaceutically acceptable addition salts or hydrates thereof.

The present invention also relates to the use of the novel compounds of the formula I as disclosed in the examples herein, and as defined in the compound claims herein, for the preparation of a medicament, especially for the preparation of a medicament for the treatment and/or prevention of hyperglycaemia or diabetes mellitus, preferably NIDDM. The compounds of the present invention reduce elevated plasma glucose levels, and hence make them useful in the treatment and prevention of various diseases of the endocrinological system, especially ailments related to carbohydrate metabolism and especially the glucose metabolism, e.g. hyperglycaemia, diabetes mellitus, and especially non-insulin dependent diabetes mellitus (NIDDM) including long-term complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy. Moreover, the present compounds are useful in the prophylactic treatment of hyperlipidaemia, hypertension, liver and bile diseases, and atherosclerosis associated with diabetes. The present compounds are especially useful

in the treatment of diseases associated with the activity of the liver enzyme glycogen phosphorylase, due to their capability of inhibiting said enzymatic activity.


Accordingly, in another aspect the invention relates to a compound of the general formula I, or a pharmaceutically acceptable acid addition salts or hydrates or prodrugs thereof for use as a therapeutically active substance, preferably for use as a therapeutically active substance in the treatment or prevention of diseases of the endocrinological system, preferably hyperglycaemia or diabetes.

10 Furthermore, the invention also relates to the use of the inventive compounds of formula I for the preparation of medicaments useful for treating or preventing hyperglycaemia or diabetes.

Moreover, the invention relates to a method of treating or preventing diseases of the endocrinological system, preferably diabetes, in a subject in need thereof comprising administering an effective amount of a compound according to the invention.


The invention also relates to methods of preparing the above mentioned compounds. These methods comprise:

20 a) Reacting a compound of formula II




wherein R<sup>5</sup> is R<sup>3</sup> optionally substituted with a protection group, preferably benzyl, 25 R<sup>6</sup> is R<sup>4</sup> optionally substituted with a protection group, preferably benzyl and R<sup>3</sup> and R<sup>4</sup> are as defined above with R<sup>1</sup> MgX wherein R<sup>1</sup> is as defined above and X is halogen, preferably bromine or chlorine, to form a compound of formula III

11




wherein  $R^2$  is oxygen and  $R^1$ ,  $R^5$  and  $R^6$  have the meanings set forth above, followed by de-benzylation and optionally deprotection of a compound of formula (III) by catalytic reduction to form a compound of the general formula (I), or

b) Reduction of a compound of formula III



10

with a reducing agent, preferably  $LiAlH_4$  in THF to form a compound of formula IV



15 wherein  $R^2$  is hydroxy and  $R^1$ ,  $R^5$  and  $R^6$  have the meanings set forth above, followed by debenzylation and optionally deprotection of a compound of formula (IV) by catalytic reduction to form a compound of the general formula (I).

The starting materials employed in the synthesis of the compounds of formula II are either known or may be prepared in conventional manner from commercially available materials, e.g according to the methods described in the examples. Other compounds of the general 5 formula I can be prepared by the above strategy. A variety of functional groups can be introduced in the compounds prepared as outlined above by methods well known to those skilled in the art.

#### Pharmaceutical Compositions

10 This invention further provides pharmaceutical compositions comprising, as an active ingredient, at least one compound of formula I or a pharmaceutically acceptable salt thereof in connection with a pharmaceutically acceptable carrier or diluent. Such compositions may be in the form of powders, solutions, suspensions, or aerosols, or which may or may not be divided in unit dosage form or in the form of capsules or tablets. Liquid compositions include 15 sterile solutions, suspensions and emulsions suitable for parenteral injection.

The pharmaceutical compositions of this invention may comprise carriers, diluents, absorption enhancers, tablet disintegrating agents and other ingredients which are conventionally used in the art. The powders and tablets preferably contain from 5 to 99%, more preferred 20 from 10 to 90% of the active ingredient. Examples of solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatine, pectin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes and cocoa butter.

25 The route of administration of the compositions containing a compound of formula I may be any route which effectively transports the active compound to its site of action, such as oral, pulmonary, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, in- traurethral or intramuscular, the oral route being preferred.

If a solid carrier is used for oral administration the preparation may be tabletted, placed in a 30 hard gelatin capsule in powder or pellet form, or it can be in the form of a troche or lozenge. If a liquid carrier is used the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or

the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, and capsules include lactose, corn starch, and/or potato starch.

5 For parenteral application particularly suitable are injectable solutions or suspensions, preferably aqueous solutons with the active compound dissolved in polyhydroxylated castor oil.

A typical tablet which may be prepared by conventional tableting techniques may contain:

Core:

10	Active compound (as free compound or salt thereof)	50 mg
	Colloidal silicon dioxide (Aerosil)	1.5 mg
	Cellulose, microcryst. (Avicel)	70 mg
	Modified cellulose gum (Ac-Di-Sol)	7.5 mg
	Magnesium stearate	Ad.

15

Coating:

HPMC approx.	9 mg
*Mywacett 9-40 T approx.	0.9 mg

20 \*Acylated monoglyceride used as plasticizer for film coating.

The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above and especially diabetes. Such mammals include also animals, 25 both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.

The regimen for any patient to be treated with the compositions according to the present invention should be determined by those skilled in the art. The daily dose to be administered in therapy can be determined by a physician and will depend on the particular compound employed, on the route of administration and on the age and the condition of the patient. 30

The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 2 to about 500 mg per day may be used.

The exact dosage will depend upon the mode of administration, on the therapy desired, form

in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.

In a further aspect, the present invention relates to a method of treating and/or preventing dia-

5 betes.

In a still further aspect, the present invention relates to the use of one or more compounds of the general formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and/or prevention of diabetes.

10

#### Experimental pharmacological protocol and results

For in vivo studies, female ob/OB mice (20 g) fasted for 3 hours were used. Test compounds or NaCl (0.9%; controls) were administered intravenously (hereinafter designated i.v.). Glucagon were administered subcutaneously (herein-after designated s.c.) in order to increase hepatic glucose output derived from glycogen. Blood samples were drawn from the orbital vein and analyzed for glucose using a glucose oxidase method.

Rat hepatocytes were isolated using a standard two step collagenase technique, and cultured onto collagen coated culture dishes for 72 hours in medium 199 with the addition of dexamethazone (0.1 mM); penicillin/Streptomycin ((100 u/100 mg)/ml) and insulin (1 nM). During the last 24 hours, the hepatocytes were cultured in the presence of high levels of insulin (5 nM) and glucose (15 mM), which result in the incorporation of glucose into glycogen. Therefore, at the time of the experiment, the cells mimic livers from fed animals.

25 Experiments were initiated after 48 hours of culture by 2 times wash of cells and addition of a 20 mM HEPES experimental buffer including balanced salts, but without glucose. The test compound was added simultaneously with the experimental buffer. To some cultures, glucagon (0.5 nM) was added after 10 minutes in order to stimulate glucose production from liver cells. The glucose released into the media, reflecting the glucose production of the liver cells, 30 was measured 70 minutes after the start of the experiment and standardized to cellular DNA content.

Phosphorylase was either purchased from Sigma or extracted from rat livers according to Stalmans et. al. (Eur.J.Biochem. 49 (1974), 415). The activity of phosphorylase was deter-

mined as described by Bergmeyer (1983; in: *Meth. of Enzymatic Analysis*, 2, 293-295, Weinheim, (ed.) Verlag Chemie).

Compounds of the invention shows their effect in lowering the glucagon mediated increase in  
5 plasma glucose.

The present invention is further illustrated by the following examples which, however, are not  
to be construed as limiting the scope of protection. The features disclosed in the foregoing  
description and in the following examples may, both separately and in any combination  
10 thereof, be material for realising the invention in diverse forms thereof.

#### Example 1

##### (3S,4S)-1-Benzyl-3,4-dihydroxy-2,5-dioxopyrrolidine

15 A mixture of D(-)-tartaric acid (4.5 g, 30 mmol), benzylamine (3.3 ml, 30.2 mmol) and m-  
xylene (50 ml) was heated at reflux temperature for 4 hours with simultaneous capture of  
water. The mixture was cooled to room temperature, filtered and washed with m-xylene  
twice (2 x 2 ml) and acetone (10 ml) to give (3S,4S)-1-benzyl-3,4-dihydroxy-2,5-  
20 dioxopyrrolidine (5.0 g, yield: 76 %) as light yellow crystals.  
MP. 195-97 °C.

#### Example 2

##### (3R,4R)-1-Benzyl-3,4-pyrrolidinediol

25 Boron trifluoride ethyl etherate (36 ml, 0.29 mol) in diglyme (150 ml) was cooled to 0 °C.  
(3S,4S)-1-Benzyl-3,4-dihydroxy-2,5-dioxopyrrolidine (16 g, 72 mmol) and sodium borohy-  
dride were added slowly. The mixture was stirred at 70 °C for 2 hours. 6 N hydrochloric acid  
30 (100 ml) was added slowly and the mixture was heated at 70 °C for 15 minutes. Sodium fluo-  
ride (44.5 g, 1 mol) was added and the mixture was heated at reflux temperature for ½ hour.  
The mixture was cooled to room temperature. 20 % Aqueous sodium hydroxide (85 ml) was  
added and the resulting mixture was filtered. The organic phase was isolated and evapo-  
rated to dryness. The residue was partitioned between water and diethyl ether. The water

phase was extracted with ether (4 x 500 ml). The collected organic phases were dried over magnesium sulphate and evaporated to dryness. Recrystallization from ethyl acetate (25 ml) gave (3R,4R)-1-benzyl-3,4-pyrrolidinediol (12.3 g, yield: 88 %) as white crystals.

Mp. 97-99.7 °C

5

Example 3

(3R,4R)-1-Benzyl-3,4-dibenzylloxypyrrolidine

10 A solution of (3R,4R)-1-benzyl-3,4-pyrrolidinediol (10 g, 51.8 mmol) in dry DMF (40 ml) was added to a suspension of 60 % sodium hydride (5 g, 125 mmol) in dry DMF (150 ml) under nitrogen air. Benzyl chloride (14 ml, 120 mmol) was added and the mixture was stirred over night at room temperature.

Water was added (10 ml) and the mixture evaporated to dryness in vacuo. The residue was

15 extracted with methylene chloride (200 ml) and ethyl acetate (50 ml). Purification of the product on silica gel (Eluent: Methylene chloride/ethyl acetate (4:1)) afforded (3R,4R)-1-benzyl-3,4-dibenzylloxypyrrolidine (15.4 g, yield: 80 %) as an oil.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15 H), 4.48 (s, 4H), 4.05 (t, 2H), 3.6 (dd, 2H), 2.9 (dd, 2H), 2.6 (dd, 2H).

20

Example 4

(3R,4R)-3,4-Dibenzylloxypyrrolidine

25 To a solution of (3R,4R)-1-benzyl-3,4-dibenzylloxypyrrolidine (26.8 g, 71.7 mmol) in methanol (600 ml) was added palladium hydroxide on activated charcoal (20 % Pd, 2.7 g) and 25 % ammonium hydroxide (6 ml). The mixture was hydrogenated in a Parr apparatus at 20 psi for 20 hours. The mixture was filtered and evaporated to dryness in vacuo to give (3R,4R)-3,4-dibenzylloxypyrrolidine (19.7 g, yield: 96 %) as an oil.

30 <sup>1</sup>H-NMR(CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 10 H), 4.48 (s, 4H), 4.0 (m, 2H), 3.15 (dd, 2H), 2.92 (dd, 2H), 2.6 (s, 1H).

Example 5(3R,4R)-3,4-Dibenzylxy-pyrrolidine-2-carbonitrile

5 N-Chlorosuccinimide (7.05 g, 52.6 mmol) was added to a solution of (3R,4R)-3,4-dibenzylxy-pyrrolidine (15 g, 52.8 mmol) in diethyl ether (300 ml). The resulting mixture was stirred at room temperature for 3 hours under a nitrogen atmosphere. Addition of toluene (250 ml) and water (200 ml), washing of the organic phase with 2 M sodium thiosulfate (200 ml) and water (200 ml), drying with magnesium sulphate gave a solution of (3R,4R)-3,4-dibenzylxy-1-chloropyrrolidine in toluene. The compound is unstable and was used without further purification.

10 The toluene solution was added to a solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (16 g, 105 mmol) in toluene (200 ml). The mixture was stirred at room temperature for 20 hours under a nitrogen atmosphere. Water (250 ml) was added, the organic phase was isolated and the water phase was extracted with toluene (100 ml). The combined organic phases were washed with water (200 ml), dried with magnesium sulphate giving a toluene solution of (3R,4R)-3,4-dibenzylxy-1-pyrrolidine. The compound is unstable and was used without further purification.

15 To the toluene solution was added zinc iodide (0.5 g) and trimethylsilyl cyanide (20 ml, 160 mmol). The mixture was stirred at room temperature for 20 hours under a nitrogen atmosphere. Dioxan (5 ml) and water (5 ml) were added and stirring was continued for 1½ hour at room temperature. Water (150 ml) was added, the organic phase isolated and washed with water (200 ml), dried with magnesium sulphate and evaporated to dryness in vacuo to give the title compound as an oil. Purification of the crude product on a silica gel column (Eluent: 20 ethyl acetate) afforded (3R,4R)-3,4-dibenzylxy-pyrrolidine-2-carbonitrile (13.5 g, yield: 82 % overall) as an oil.

25 <sup>1</sup>H-NMR(CDCl<sub>3</sub>) in ppm: δ 7.33 (m, 10 H), 4.48-4.7 (m, 4H), 3.9-4.3 (m, 3H), 3.4-3.0 (m, 2H), 2.2 (broad s, 1H).

Example 6(3R,4R)-1-Benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile

5 A mixture of (3R,4R)-3,4-dibenzylxy-pyrrolidine-2-carbonitrile (13 g, 42.2 mmol), potassium carbonate (8.7 g, 63 mmol), potassium iodide (0.1 g), benzyl bromide (7.5 ml, 63.2 mmol) and acetone (200 ml) were heated at reflux temperature for 4 hours. The mixture was cooled, filtered and the filtrate evaporated to dryness in vacuo to give the title compound as an oil. Purification of the crude product on a silica gel column (Eluent: From 100 % heptane

10 to 100 % ethyl acetate) afforded (3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile (8.2 g, yield: 49 %) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15 H), 4.4-4.6 (m, 4H), 3.55-4.3 (m, 5H), 3.2-2.6 (m, 2H).

The oil of 1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile contains a mixture of two

15 stereoisomers. A small amount of the two isomers were isolated on a reverse phase C18 column (Eluent: Acetonitrile:water (7:1) + 0.1 % trifluoroacetic acid) giving 540 mg of (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile as an light yellow oil

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15 H), 4.55 (d, 2H), 4.5 (s, 2H), 4.23 (t, 1H), 4.1 (m, 1H), 3.8 (d.d, 2H), 3.5 (s, 1H), 3.2-2.6 (m, 2H);

20 and 300 mg of (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile as an light brown oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.35 (m, 15H), 4.6 (d.d, 2H), 4.5 (d, 2H), 4.2 (m, 2H), 4.0 (d, 1H), 3.7 (d.d, 2H), 3.5 (s, 1H), 2.95 (m, 2H).

25

Example 7(3R,4R)-1-Benzyl-3,4-dibenzylxy-2-acetylpyrrolidine

30 3 M Methylmagnesium chloride in tetrahydrofuran (0.6 ml, 1.8 mmol) was added slowly at reflux temperature to a solution of (3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile (250 mg, 0.63 mmol) in diethyl ether. The mixture was heated at reflux temperature for 1

hour, cooled to room temperature and added 0.5 N hydrochloric acid (5 ml). The organic phase was isolated, washed with water (2 x 5 ml), dried over magnesium sulphate and concentrated in vacuo to give the title compound as an oil (200 mg, yield: 77 %). Purification of the crude product on a silica gel column (Eluent: methylene chloride) afforded (3R,4R)-1-

5 benzyl-3,4-dibenzylxy-2-acetylpyrrolidine as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15 H), 4.4-4.6 (m, 4H), 3.2-4.3 (m, 6H), 2.3-2.7 (m, 1H), 2.2 (s, 3H).

In a similar way the following compounds were prepared:

10 (2R,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-acetylpyrrolidine from methylmagnesium chloride and (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15H), 4.4-4.7 (m, 4H), 4.03 (m, 1H), 3.95 (m, 1H), 3.7 (d,d,2H), 3.6 (d,1H), 2.6-3.2 (m, 2H), 2.2 (s, 3H);

15 (2S,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-acetylpyrrolidine from methylmagnesium chloride and (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15H), 4.4-4.7 (m, 4H), 4.25 (m, 1H), 4.12 (m, 1H), 3.7 (d,d,2H), 3.5 (m, 1H), 3.4 (m, 1H), 2.4 (d,d,1H), 2.18 (s, 3H);

20 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-valerylpyrrolidine from butylmagnesium bromide and (3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15H), 4.3-4.7 (m, 4H), 3.7-4.1 (m, 3H), 3.1-3.5 (m, 3H), 2.1-2.7 (m, 3H), 1.1-1.6 (m, 4H), 0.8-1.0 (m, 3H);

25 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-tridecanoylpyrrolidine from dodecylmagnesium iodide and (3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15H), 4.4-4.7 (m, 4H), 3.8-4.3 (m, 3H), 3.1-3.7 (m, 2H), 2.3-2.7 (m, 2H), 1.2-1.6 (m, 22H), 0.9 (b,d,3H);

30 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(4-cyclohexylbutanoyl)pyrrolidine from 3-cyclohexylpropylmagnesium chloride and (3R,4R)-1-benzyl-3,4-dibenzylxy-pyrrolidine-2-carbonitrile.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m,15H), 4.4-4.6 (m,4H), 3.1-4.1 (m,5H), 2.1-2.7 (m,3H), 1.0-1.8 (m,21H), 0.7-0.95 (m,3H);

(3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(4-phenylbutanoyl)pyrrolidine from 3-

5 phenylpropylmagnesium bromide and (3R,4R)-1-benzyl-3,4-dibenzylxyprrolidine-2-carbonitrile.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m,20H), 4.3-4.7 (m,4H), 3.1-4.0 (m,6H), 2.4-2.7 (m,5H), 1.8 (p,2H);

10 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-propionylpyrrolidine from ethylmagnesium bromide and (3R,4R)-1-benzyl-3,4-dibenzylxyprrolidine-2-carbonitrile.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m,15H), 4.4-4.7 (m,4H), 3.4-4.1 (m,4H), 3.1-3.4 (m,2H), 2.3-2.8 (m,3H), 0.9 (t,3H).

15 Example 8

(3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine

1 M lithium aluminiumhydride in tetrahydrofuran (1.5 ml, 1.5 mmol) was added slowly to a

20 solution of (3R,4R)-1-benzyl-3,4-dibenzylxy-2-acetylpyrrolidine (390 mg, 0.94 mmol) in dry tetrahydrofuran (5 ml) at 0-5 °C. Stirring was continued for 1½ hour at room temperature.

Water (1 ml) was slowly added. The mixture was filtered and the filtrate was evaporated to dryness in vacuo to give the title compound as an oil. Purification of the crude product on a silica gel column (Eluent: methylene chloride: ethyl acetate (9:1)) afforded (3R,4R)-1-benzyl-

25 3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine (90 mg, yield 23 %) as an oil.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15 H), 4.4-4.7 (m,4H), 3.9-4.2 (m, 4H), 3.38 (d,1H), 3.05 (d, 1H), 2.5-2.8 (m, 2H), 1.2-1.3 (m, 3H).

In a similar way the following compounds were prepared:

30 (2R,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine from (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-2-acetylpyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm: δ 7.3 (m, 15 H), 4.45-4.55 (m,4H), 3.9-4.1 (m, 4H), 3.38 (d,1H), 3.05 (d, 1H), 2.5-2.6 (m, 2H), 1.18 (d, 3H).

(2S,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine from (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-2-acetylpyrrolidine.

5 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxypentyl)pyrrolidine from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-valerylpyrrolidine;

(3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxytridecyl)pyrrolidine from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-tridecanoylpyrrolidine.

10 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(4-cyclohexyl-1-hydroxybutyl)pyrrolidine from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(4-cyclohexylbutanoyl)pyrrolidine;

15 (3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxy-4-phenylbutyl)pyrrolidine from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(4-phenylbutanoyl)pyrrolidine;

20 (2R,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine can be separated on an optically active column into (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1R)-1-hydroxyethyl)pyrrolidine and (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1S)-1-hydroxyethyl)pyrrolidine;

25 (2S,3R,4R)-1-Benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine can be separated on an optically active column into (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1R)-1-hydroxyethyl)pyrrolidine and (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1S)-1-hydroxyethyl)pyrrolidine.

### Example 9

30 (3R,4R)-2-(1-Hydroxyethyl)-3,4-pyrrolidinediol ( Compound 1)

To a solution of (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(1-hydroxyethyl)pyrrolidine (90 mg, 0.22 mmol) in abs. ethanol (10 ml) was added palladium on activated charcoal (10 % Pd, 30 mg) and 37 % hydrochloric acid (0.1 ml). The mixture was hydrogenated in a Parr apparatus at

40 psi for 20 hours. The mixture was filtered and evaporated to dryness in vacuo to give (3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol (36 mg, yield: 90 %) as an oil.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  4.25 (m, 1H), 4.15 (m, 1H), 4.0 (m, 1H), 3.3-3.5 (m, 3H), 1.3 (d, 3H).

5

In a similar way the following compounds were prepared:

(3R,4R)-2-(1-Hydroxypentyl)-3,4-pyrrolidinediol (Compound 2) from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(1-hydroxypentyl)pyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  4.25 (m, 1H), 4.15 (m, 1H), 3.8 (m, 1H), 3.2-3.5 (m, 3H), 1.3-1.7 (m, 6H), 0.95 (t, 3H);

(3R,4R)-2-(1-Hydroxytridecyl)-3,4-pyrrolidinediol (Compound 3) from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(1-hydroxytridecyl)pyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  3.1-4.3 (m, 6H), 1.2-1.7 (m, 22H), 0.9 (t, 3H).

15

(2R,3R,4R)-2-((1R)-1-Hydroxyethyl)-3,4-pyrrolidinediol (Compound 4) from (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1R)-1-hydroxyethyl)pyrrolidine;

(2R,3R,4R)-2-((1S)-1-Hydroxyethyl)-3,4-pyrrolidinediol (Compound 5) from (2R,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1S)-1-hydroxyethyl)pyrrolidine;

(2S,3R,4R)-2-((1R)-1-Hydroxyethyl)-3,4-pyrrolidinediol (Compound 6) from (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1R)-1-hydroxyethyl)pyrrolidine;

(2S,3R,4R)-2-((1S)-1-Hydroxyethyl)-3,4-pyrrolidinediol (Compound 7) from (2S,3R,4R)-1-benzyl-3,4-dibenzylxy-2-((1S)-1-hydroxyethyl)pyrrolidine;

(3R,4R)-2-(1-Hydroxyphenylbutyl)-3,4-pyrrolidinediol (Compound 8) from (3R,4R)-1-benzyl-3,4-dibenzylxy-2-(1-hydroxyphenylbutyl)pyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  7.1-7.5 (m, 5H), 3.4-4.7 (m, 6H), 2.5-2.7 (m, 1H), 2.1-2.2 (m, 1H), 1.2-1.9 (m, 4H);

(3R,4R)-2-Acetyl-3,4-pyrrolidinediol (Compound 9) from (3R,4R)-2-acetyl-1-benzyl-3,4-dibenzyloxyppyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  4.2-4.8 (m, 2H), 3.3-3.7 (m, 3H), 2.4 (s, 3H);


5 (3R,4R)-2-(1-Hydroxypropyl)-3,4-pyrrolidinediol (Compound 10) from (3R,4R)-1-benzyl-3,4-dibenzyloxy-2-propionylpyrrolidine.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) in ppm:  $\delta$  4.2-4.3 (m, 2H), 3.7-3.8 (m, 1H), 3.2-3.5 (m, 3H), 1.3-1.7 (m, 2H), 0.9 (t, 3H).

CLAIMS

## 1. Pyrrolidine compounds having the general formula I

5



and pharmaceutically acceptable acid addition salts or hydrates or prodrugs hereof, wherein

10 R<sup>1</sup> is straight or branched C<sub>1-14</sub>-alkyl optionally substituted with C<sub>3-7</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, phenoxy, perhalomethyl, halogen, optionally substituted phenyl;

C $\equiv$  R<sup>2</sup> is optionally C $\equiv$  R<sup>2</sup> or C—R<sup>2</sup>

15 R<sup>2</sup> is oxygen, hydroxy, halogen, amino or mercapto,R<sup>3</sup> and R<sup>4</sup> independently are hydroxy, halogen, amino or mercapto.

2. A compound according to claim 1 wherein C $\equiv$  R<sup>2</sup> is C-R2 wherein R2 has the meaning  
20 defined above.

3. A compound according to claim 2 wherein R2 is hydroxy.

4. A compound according to any of claims 1 to 3 wherein R3 and R4 are hydroxy.

25

5. A compound according to any of the preceding claims and selected from the group consisting of:

(3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,  
(3R,4R)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,

(3R,4R)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,  
(3R,4R)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(3R,4R)-2-(1-hydroxyphenylbutyl)-3,4-pyrrolidinediol, and  
(3R,4R)-2-acetyl-3,4-pyrrolidinediol,  
5 or a pharmaceutically acceptable salts or hydrates thereof, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

6. An optical isomer or mixture of optical isomers, including a racemic mixture according to claim 2 selected from the group consisting of:

10 (2R,3R,4R)-2-acetyl-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,  
15 (2R,3R,4R)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-acetyl-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-(1-hydroxypentyl)-3,4-pyrrolidinediol,  
20 (2S,3S,4S)-2-(1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1R)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-(1R)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1R)-1-hydroxypentyl)-3,4-pyrrolidinediol,  
25 (2S,3S,4S)-2-((1R)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxypentyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1R)-1-hydroxytridecyl)-3,4-pyrrolidinediol,  
30 (2R,3R,4R)-2-((1S)-1-hydroxyethyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1S)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2R,3R,4R)-2-((1S)-1-hydroxytridecyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1S)-1-hydroxyethyl)-3,4-pyrrolidinediol,

(2S,3S,4S)-2-((1S)-1-hydroxypropyl)-3,4-pyrrolidinediol,  
(2S,3S,4S)-2-((1S)-1-hydroxypentyl)-3,4-pyrrolidinediol, and  
(2S,3S,4S)-2-((1S)-1-hydroxytridecyl)-3,4-pyrrolidinediol,  
or a pharmaceutically acceptable salt or hydrate thereof.

5


7. A compound according to any one of the preceding claims which is active as an inhibitor of glucose production.

10 8. A compound according to any one of the preceding claims which is active as an inhibitor

of glycogen phosphorylase enzymatic activity.

9. A method of preparing a compound of formula I, characterized in

15 a) Reacting a compound of formula II




20

wherein R<sup>5</sup> is R<sup>3</sup> optionally substituted with a protection group, preferably benzyl, R<sup>6</sup> is R<sup>4</sup> optionally substituted with a protection group, preferably benzyl and R<sup>3</sup> and R<sup>4</sup> are as defined above with R<sup>1</sup> MgX wherein R<sup>1</sup> is as defined above and X is halogen, preferably bromine or chlorine, to form a compound of formula III

25


27



(III)

wherein R<sup>2</sup> is oxygen and R<sup>1</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings set forth above, followed by de-benzylation and optionally deprotection of a compound of formula (III) by catalytic reduction  
 5 to form a compound of the general formula (I), or


b) Reduction of a compound of formula III



(III)

10

with a reducing agent, preferably LiAlH<sub>4</sub> in THF to form a compound of formula IV



(IV)

15 wherein R<sup>2</sup> is hydroxy and R<sup>1</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings set forth above, followed by de-benzylation and optionally deprotection of a compound of formula (IV) by catalytic reduction to form a compound of the general formula (I).

10. A pharmaceutical composition comprising a compound according to any of the claims 1 - 8 or a pharmaceutical acceptable salt thereof, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or 5 more pharmaceutically acceptable carriers or diluents.
11. A pharmaceutical composition for use in the treatment of diseases of the endocrinological system, preferably diabetes, comprising a compound according to any of the claims 1 - 8 or a pharmaceutical acceptable salt thereof, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or 10 more pharmaceutically acceptable carriers or diluents.
12. The pharmaceutical composition according to claim 10 or 11 in the form of an oral dosage unit or parenteral dosage unit. 15
13. A pharmaceutical composition according to claim 10 or 11 wherein said compound is administered as a dose in a range from about 2 to 500 mg per day.
14. A compound according to any one of the claims 1 - 8 or a pharmaceutically acceptable 20 salt thereof, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use.
15. A compound according to any one of the claims 1 - 8 or a pharmaceutically acceptable salt thereof, or any optical isomer or mixture of optical isomers, including a racemic 25 mixture, or any tautomeric form for therapeutical use in the treatment or prevention of diseases of the endocrinological system, preferably diabetes.
16. The use of a compound according to any one of the claims 1 - 8 or a pharmaceutically acceptable salt thereof, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form as a medicament. 30
17. The use of a compound according to any of the claims 1 - 8 for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system, preferably diabetes.

18. A method of treating or preventing diseases of the endocrinological system, preferably diabetes in a subject in need thereof comprising administering an effective amount of a compound according to any of the claims 1 - 8 to said subject.
- 5 19. A process for the manufacture of a medicament, particular to be used in the treatment or prevention of diseases of the endocrinological system, preferably diabetes which process comprises bringing a compound of formula I according to any of the claims 1 - 8 into a galenic dosage form.
- 10 20. Any novel feature or combination of features as described herein.

1  
INTERNATIONAL SEARCH REPORT

International application No. PCT/DK 98/00084
--

**A. CLASSIFICATION OF SUBJECT MATTER**

**IPC6: C07D 207/12, A61K 31/40**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC6: C07D**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**SE,DK,FI,NO classes as above**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**CAS-ONLINE**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4996329 A (GEORGE W.J. FLEET ET AL), 26 February 1991 (26.02.91), see compound 9,12,14, 16,18	1-15,19
A	--	17
X	Tetrahedron, Volume 48, No 16, 1992, Antony J. Fairbanks et al, "Synthesis of, and Lack of Inhibition of a Rhamnosidase by, Both Enantiomers of Deoxyrhamnolipin and Rhamnolactam: Beta-Mannosidase inhibition by delta-lactams", page 3365 - page 3376, see especially page 3369, compound 4	1-6,9
A	--	7-8,10-15, 17,19

Further documents are listed in the continuation of Box C.

See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

17 June 1998

Date of mailing of the international search report

26-06-1998

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. + 46 8 666 02 86

Authorized officer  
  
Göran Karlsson  
Telephone No. + 46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00084

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Tetrahedron Letters, Volume 36, No 41, 1995, Tilmann W. Brandstetter et al, "Tetrazoles of Manno- and Rhamno-Pyranoses: Inhibition of Glycosidases by Tetrazoles and Other Mannose Mimics", page 7511 - page 7514, see compound 21	1-6,9
A		7-8,10-15, 17,19
	---	
X	Biochem J., Volume 290, 1993, Bryan Winchester et al, "The structural basis of the inhibition of human alpha-mannosidases by azafuranose analogues of mannose", page 743 - page 749, see compound 7 and 8	1-6,9
A		7-8,10-15, 17,19
	---	
A	WO 9709040 A1 (NOVO NORDISK A/S), 13 March 1997 (13.03.97)	1-15,17,19
	---	
A	Journal of Traditional Medicines, Volume 12, 1995, Masayasu Kimura et al, "Antihyperglycemic effects of N-containing sugars derived from Mulberry leaves in streptozocin-induced diabetic mice" page 214 - page 219	1-15,17,19
	---	
	-----	

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 98/00084

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 16 and 18  
because they relate to subject matter not required to be searched by this Authority, namely:  
A method for treatment of the human or animal body by therapy,  
see rule 39.1.
2.  Claims Nos.: 20  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claim 20 is obscure and does not define the matter for which protection is sought. A meaningful search of this claim has therefore not been performed, see Article 6.
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

09/06/98

International application No. PCT/DK 98/00084	
--	--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4996329 A	26/02/91	AT 117992 T	15/02/95
		CA 2028048 A	21/04/91
		CA 2028076 A	21/04/91
		DE 69016571 D, T	07/09/95
		DK 424350 T	10/04/95
		EP 0424349 A	24/04/91
		EP 0424350 A, B	24/04/91
		SE 0424350 T3	
		ES 2069060 T	01/05/95
		JP 3135982 A	10/06/91
		JP 3151359 A	27/06/91
		US 5023340 A	11/06/91
		US 5041555 A	20/08/91
		US 5075448 A	24/12/91
		US 5075457 A	24/12/91
-----	-----	-----	-----
WO 9709040 A1	13/03/97	AU 6785996 A	27/03/97
-----	-----	-----	-----